Novelos begins Phase I/II

Novelos Therapeutics (Newton, Mass.) began a U.S. Phase I/II trial of its BAM-002 in combination with chemotherapy to treat non-small lung cancer (NSCLC). BAM-002 is an oxidized form of a human peptid...